Angiogenesis and cancer metastasis

Cancer Journal

Volumn 6, Issue SUPPL. 2, 2000, Pages

  Fidler, Isaiah J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Angiogenesis; Cancer metastasis; Interferon; Proangiogenic and antiangiogenic molecules

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; BETA INTERFERON; GELATINASE A; INTERLEUKIN 8;

CANCER GROWTH; DOWN REGULATION; EXPERIMENTAL NEOPLASM; HUMAN; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STROMA CELL; TRANSCRIPTION REGULATION; TUMOR VASCULARIZATION;

ANIMALS; HUMANS; LYMPHOCYTES; MACROPHAGES; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0033914013     PISSN: 15289117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res 1990;50: 6130-6138.
2. Fidler IJ. Modulation of the organ microenvironment for the treatment of cancer metastasis. J Nat Cancer Inst 1995;84:1588-1592.
3. Fidler IJ, Kripke ML. Metastasis results from pre-existing variant cells within a malignant tumor. Science 1977; 197:893-895.
4. Fidler IJ, Talmadge JE. Evidence that intravenously derived murine pulmonary melanoma metastases can originate from the expansion of a single tumor cell. Cancer Res 1986; 46:5167-5171.
5. Poste G, Fidler IJ. The pathogenesis of cancer metastasis. Nature 1980;283:139-146.
6. Aukerman SL, Price JE, Fidler IJ. Different deficiencies in the prevention of tumorigenic-low-metastatic murine K-1735 melanoma cells from producing metastases. J Nat Cancer Inst 1986;77:915-924.
7. Folkman J. Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nature Med 1995;1:27-31.
8. Auerbach W, Auerbach R. Angiogenesis inhibition: a review. Pharmac Ther 1994;63:265-311.
9. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994;47: 185-188.
10. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;235:444-447.
11. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-336.
12. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
13. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991;51:5054S-5059S.
14. 125I-5-iodo-2'-deoxyuridine. J Nat Cancer Inst 1970;45:773-782.
15. Weiss L. Principles of Metastasis. Orlando: Academic Press, 1985.
16. Nicolson GL. Metastatic tumor cell interactions with endothelium, basement membrane, and tissue. Curr Opin Cell Biol 1989;1:1009-1019.
17. Fidler IJ, Nicolson GL. Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J Nat Cancer Inst 1976;57:1199-1202.
18. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 188;i:571-573.
19. Ewing J. Neoplastic Diseases. 6th ed. Philadelphia: WB Saunders, 1928.
20. Sugarbaker EV. Cancer metastasis: a product of tumor-host interactions. Curr Prob Cancer 1979;3:1-59.
21. Poste G. Experimental systems for analysis of the malignant phenotype. Cancer Metastasis Rev 1982;1:141-199.
22. Fujimaki T, Price JE, Fan D et al. Selective growth of human melanoma cells in the brain parenchyma of nude mice. Melanoma Res 1996;6:363-371.
23. Hart IR. "Seed and soil" revisited: mechanisms of site-specific metastasis. Cancer Metastasis Rev 1982;1:5-16.
24. Hart IR, Fidler IJ. Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res 1980;41:2281-2287.
25. Tarin D, Price JE, Kettlewell MGW et al. Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res 1984;44:3584-3590.
26. Tarin D, Price JE, Kettlewell MGW et al. Clinicopathological observations on metastasis in man studied in patients treated with peritoneovenous shunts. Br Med J 1984;288:749-751.
27. Radinsky R, Aukerman SL, Fidler IJ. The heterogeneous nature of metastatic neoplasms: relevance to biotherapy. In: Oldham RK, ed. Principles of Cancer Biotherapy. 3rd ed. Boston: Kluwer Academic, 1998:16-38.
28. Talmadge JE, Fidler IJ. Cancer metastasis is selective or random depending on the parent tumor population. Nature 1982;27:593-594.
29. Fidler IJ. Selection of successive tumor lines for metastasis. Nature (New Biol) 1973;242:148-149.
30. Fidler IJ, Poste G. The cellular heterogeneity of malignant neoplasms: implications for adjuvant chemotherapy. Semin Oncol 1985;12:207-222.
31. Fidler IJ, Gersten DM, Kripke ML. Influence of immune status on the metastasis of three murine fibrosarcomas of different immunogenicities. Cancer Res 1979;39:3816-3821.
32. Talmadge JE, Wolman SR, Fidler IJ. Evidence for the clonal origin of spontaneous metastasis. Science 1982;217:361-363.
33. Fidler IJ. Orthotopic implantation of human colon carcinomas into nude mice provides a valuable model for the biology and therapy of cancer metastasis. Cancer Metastasis Rev 1991;10:229-243.
34. Ellis LJ, Fidler IJ. Angiogenesis and metastasis. Eur J Cancer 1996;32A:2451-2460.
35. Weidner N, Folkman J, Pozza F et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma. J Nat Cancer Inst 1992;84:1875-1887.
36. Weidner N, Carroll PR, Flax J et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-409.
37. Weidner N, Folkman J. Tumoral vascularity as a prognostic factor in cancer. In: DeVita VT, Hellman S, Rosenberg SA, eds. Important Advances in Oncology. Philadelphia: Lippincott-Raven, 1996:167-190.
38. Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 1974;34:997-1003.
39. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes Memorial Award Lecture. Cancer Res 1986;46:467-473.
40. Gerlowski LE, Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvasc Res 1986;31:288-305.
41. Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. Adv Cancer Res 1969;69:135-144.
42. Dameron KM, Volpert OV, Tainsky MA et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1502-1504.
43. Risau W. What, if anything, is an angiogenic factor? Cancer Metastasis Rev 1996;15:149-151.
44. Dvorak HF, Brown LF, Detmar M et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-1039.
45. Brown LF, Berse B, Jackman RW et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993;53:5727-5735.
46. Yoshiji H, Gomez DE, Shibuya M et al. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res. 1996;56:2013-2016.
47. Takahashi Y, Kitadai Y, Bucana CD et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995;55:3964-3968.
48. Xerri L, Bettyeni Z, Grob JJ et al. Expression of FGF1 and FGFR1 in human melanoma tissues. Melanoma Res 1996;6:223-230.
49. Takanami I, Tanaka F, Hashizume T et al. The basic fibroblast growth factor and its receptor in pulmonary adenocarcinomas: an investigation of their expression as prognostic markers. Eur J Cancer 1996;32A: 1504-1509.
50. Kumar R, Kuniyasu H, Bucana CD et al. Spatial and temporal expression of angiogenic molecules during tumor growth and progression. Oncol Res 1998;10:301-311.
51. Kitadai Y, Ellis LM, Tucker SL et al. Multiparametric in situ hybridization analysis to predict disease recurrence in patients with colon carcinoma. Am J Pathol 1996;149:1541-1551.
52. Greene GF, Kitadai Y, Pettaway CA et al. Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am J Pathol 1997;150:1571-1582.
53. Anzai H, Kitadai Y, Bucana CD et al. Intratumoral heterogeneity and inverse correlation between expression of E-cadherin and collagenase type IV in human gastric carcinomas. Differentiation 1996;60:119-127.
54. Benjamin LE, Keshet E. Conditioned switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Nat Acad Sci 1997;84:8761-8766.
55. Alon T, Hemo I, Peter J et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995;1:1024-1028.
56. Brown LF, Berse B, Tognzaai K et al. Vascular permeability factor messenger RNA and protein expression in human kidney. Kidney Int 1992;42:1457-1461.
57. Christofori G, Naik P, Hanahan D. Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol Endocrinol 1995;9:1760-1770.
58. Kumar R, Yoneda J, Bucana CD et al. Regulation of distinct steps of angiogenesis by different angiogenic molecules. Int J Oncol 1998;12:749-757.
59. Czubayko F, Liaudet-Coopman EDE, Aigner A et al. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med 1997;3:1137-1140.
60. Czubayko F, Schulte AM, Berchem GJ et al. Melanoma angiogenesis and metastasis modulated by ribozyme targeting the secreted growth factor pleiotrophin. Proc Nat Acid Sci 1996;93:14753-14758.
61. Rak J, Kerbel RS. bFGF and tumor angiogenesis - back in the limelight? Nat Med 1997;3:1083-1084.
62. Stavri AT, Zachary IC, Baskerville PA et al. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells: synergistic interaction with hoopla. Circulation 1995;92:11-14.
63. Deroanne CF, Hajitou A, Calberg-Bacq CM et al. Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine upregulation of vascular endothelial growth factor expression. Cancer Res 1997;57:5590-5597.
64. Mandriota SJ, Pepper MS. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J Cell Sci 1997;110:2293-2302.
65. Asahara T, Bauters C, Zheng LP et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995;92:365-371.
66. Goto F, Goto K, Weindel K et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest 1993;69:508-517.
67. Singh RK, Bucana CD, Gutman M et al. Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. Am J Pathol 1994;145:365-374.
68. Singh RK, Llansa N, Bucana CD et al. Cell density-dependent regulation of basic fibroblast growth factor expression in human renal cell carcinoma cells. Cell Growth Differen 1996;7:397-404.
69. Herlyn M. Human melanoma: development and progression. Cancer Metastasis Rev 1990;9:101-112.
70. Bielenberg DR, Bucana CD, Sanchez R et al. Molecular regulation of UV-B-induced cutaneous angiogenesis. J Inv Dermatol 1998;3:864-872.
71. Singh RK, Gutman M, Radinsky R et al. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 1994; 54:3242-3247.
72. Gutman M, Singh RK, Xie K et al. Regulation of IL-8 expression in human melanoma cells by the organ environment. Cancer Res 1995;55:2470-2475.
73. Noh R, Karp GI, Devereaux DF. The effect of DXR and mitoxanthrone on wound healing. Cancer Chemother Pharmacol 1991;29:141-146.
74. Brocker EG, Rechenbeld C, Hamm H et al. Macrophages in melanocytic naevi. Arch Dermatol Res 1992;284:127-131.
75. Ruiter DJ, Bhan AK, Harris TJ et al. Major histocompatibility antigens and the mononuclear inflammatory infiltrate in benign nevomelanocytic proliferation and malignant melanoma. J Immunol 1982;129:2808-2912.
76. Fidler IJ. Lymphocytes are not only immunocytes. Biomedicine 1980;32:1-3.
77. Dvorak HF. Tumors: wounds that do not heal. N Engl J Med 1986;315:1650-1659.
78. Coman DR, Sheldon WF. The significance of hypermia around tumor implants. Am J Pathol 1946;22:821-830.
79. Sidky YA, Auerbach R. Lymphocyte-induced angiogenesis: a quantitative and sensitive assay of the graft vs. host reaction. J Exp Med 1975;141:1084-1091.
80. Sidky YA, Auerbach R. Lymphocyte-induced angiogenesis in tumor-bearing mice. Science 1976;192:1237-1238.
81. Gutman M, Singh RK, Yoon S et al. Leukocyte-induced angiogenesis and subcutaneous growth of B16 melanoma. Cancer Biother 1994; 9:163-170.
82. Fidler IJ, Gersten DM. Effect of syngeneic lymphocytes on the vascularity, growth, and induced metastasis of the B16 melanoma. In: Crispen R, ed. Neoplasm Immunity: Experimental and Clinical. New York: North Holland, 1980:3-15.
83. Killion JJ, Bucana CD, Radinsky R et al. Maintenance of intestinal epithelium structural integrity and mucosal leukocytes during chemotherapy by oral administration of muramyl tripeptide phosphatidylethanolamine. Cancer Biother Radiopharmaceut 1996;11:363-371.
84. Fidler IJ, Gersten DM, Kripke ML. Influence of immune status on the metastasis of three murine fibrosarcomas of different immunogenicities. Cancer Res 1979;39:3816-3821.
85. Wilmanns C, Fan D, O'Brian CA et al. Modulation of DXR sensitivity and level of P-glycoprotein expression in human colon carcinoma cells by ectopic and orthotopic environments in nude mice. Int J Oncol 1993;3:413-422.
86. Teicher BA, Holden SA, Al-Achi A et al. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSC murine fibrosarcoma. Cancer Res 1990;50: 3339-3345.
87. Killion JJ, Brown DR, Wilson MR et al. Prevention of chemotherapy-or X-irradiation-induced monocytopenia by oral administration of lipophilic muramyl tripeptide. Oncol Res 1994;6:357-364.
88. Peoples GE, Blotnick S, Takahashi K et al. T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: a potential pathologic role. Proc Nat Acad Sci 1995;92:6547-6551.
89. Yoneda J, Killion JJ, Bucana CD et al. Angiogenesis and growth of murine colon carcinoma are dependent on infiltrating leukocytes. Cancer Biother Radiopharm 1999; 14:221-230.
90. Leek RD, Harris AL, Lewis CE. Cytokine networks in solid human tumors: regulation of angiogenesis. J Leukoc Biol 1994;56:423-435.
91. Maccubin DL, Wing KR, Mace F et al. Adriamycin-induced modulation of host defenses in tumor-bearing mice. Cancer Res 1992;52:3572-3576.
92. Schirner M., Hoffmann J, Menrad A et al. Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. Clin Cancer Res 1998;4:1331-1336.
93. O'Sullivan C, Lewis CE. Tumor-associated leukocytes: friends or foes in breast carcinoma. Int J Pathol 1994; 172:229-235.
94. Polverini P, Cotran R, Gimbrone N et al. Activated macrophages induce vascular proliferation. Nature 1977;269:804-808.
95. Sunderkotter C, Steinbrink K, Goebeler M et al. Macrophages and angiogenesis. J Leukoc Biol 1994;55:410-422.
96. Elgert KD, Alleva DG, Mullins DW. Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 1998;64:275-280.
97. Leek RD, Lewis CE, Whitehouse R et al. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996;56:4625-4631.
98. Freeman MR, Schneck FX, Gagnon ML et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 1995;55:4140-4145.
99. Takahashi K, Mulliken JB, Kozakewich HPW et al. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994;93:2357-2361.
100. Glowacki J, Mulliken JB. Mast cells in hemangiomas and vascular malformations. Pediatrics 1982;70:48-52.
101. Takahashi Y, Kitadai Y, Bucana CD et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995;55:3964-3970.
102. Takahashi Y, Bucana CD, Liu W et al. Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Natl Cancer Inst 1996;88: 1146-1151.
103. Polverini JJ, Leibovich SJ. Induction of neovascularization in vivo and endothelial cell proliferation in vitro by tumor-associated macrophages. Lab Invest 1984;51:635-642.
104. Polverini PJ. How the extracellular matrix and macrophages contribute to angiogenesis-dependent diseases. Eur J Cancer 1996;32A:2430-2437.
105. Ingber D. Extracellular matrix and cell shape: potential control points for inhibition of angiogenesis. J Cell Biochem 1991;47:236-241.
106. Ingber DE, Folkman J. How does extracellular matrix control capillary morphogenesis? Cell 1989;58:803-805.
107. Sunderkotter C, Steinbrink K, Goebeler M et al. Macrophages and angiogenesis. J Leukoc Biol 1994;55:410-422.
108. DiPietro LA, Polverini PJ. Angiogenic macrophages produce the angiogenic inhibitor thrombospondin-1. Am J Pathol 1993;143:678-684.
109. Lingen MW, Polverini PJ, Bouck N. Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells. Lab Invest 1996;74:476-483.
110. Lingen MW, Polverini PJ, Bouck N. Retinoic acid induces cells cultured from oral squamous cell carcinomas to become antiangiogenic. Am J Pathol 1996;149:247-258.
111. O'Reilly MS, Holmgren L, Shing Y et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-328.
112. Dong Z, Kumar R, Yang X et al. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997;88:801-810.
113. Kumar R, Dong Z, Fidler IJ. Differential regulation of metalloelastase activity in murine peritoneal macrophages by GM-CSF and M-CSF. J Immunol 1996;157:5104-5111.
114. Dong Z, Yoneda J, Kumar R et al. Angiostatin-mediated suppression of cancer metastases by primary neoplasms engineered to produce granulocyte/macrophage colony-stimulating factor. J Exp Med 1998;188:755-763.